Physician profile
Jonathan C Saxe
NPI 1073588976
$2,394.77
in general payments reported to CMS, 2019-2025
23 companies · $635 in 2025
The $635 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2020: $20.00 · 2022: $179 · 2023: $503 · 2024: $912 · 2025: $635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,051.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,051.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $783.16 | 2019-2025 | Linzess, Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $285.10 | 2023-2025 | Stelara, Tremfya |
| Genzyme Corporation | $213.60 | 2022-2024 | |
| Celgene Corporation | $154.48 | 2023-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $149.87 | 2023-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $125.51 | 2024-2025 | Entyvio, Eohilia |
| Regeneron Healthcare Solutions, INC. | $116.62 | 2023-2025 | Dupixent |
| Qol Medical, LLC | $99.15 | 2023-2025 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $85.45 | 2019 | |
| Phathom Pharmaceuticals, INC. | $58.55 | 2024 | Voquezna |
| Madrigal Pharmaceuticals | $49.83 | 2025 | Rezdiffra |
| Pharmacosmos Therapeutics INC. | $35.36 | 2024-2025 | Monoferric |
| Evoke Pharma, INC. | $29.42 | 2024 | |
| Vivus LLC | $24.39 | 2019 | |
| Pfizer INC. | $23.91 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $23.66 | 2024 | |
| Aimmune Therapeutics, INC. | $23.13 | 2025 | Vowst |
| Celltrion USA INC. | $21.52 | 2025 | Vegzelma |
| Lilly USA, LLC | $21.05 | 2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $19.31 | 2023 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $19.23 | 2025 | Iqirvo |
| Acell, INC. | $16.65 | 2019 | |
| Fresenius Kabi USA, LLC | $15.82 | 2024 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Saxe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.